Gene expression profiling in acute myeloid leukaemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukaemia (AML) is a complex blood cancer defined by malignant cell proliferation and differentiation arrest.
• AML classification has evolved from morphology (FAB) to include cytogenetic and molecular abnormalities (e.g., FLT3-ITD, NPM1, CEBPA mutations).
• The World Health Organization (WHO) 2008 classification integrates these diverse factors to characterize AML subtypes.

Purpose of the Study:

• To review current AML classification variables.
• To discuss the role of microarrays in AML classification and prognosis.
• To explore how understanding AML pathobiology informs tailored therapies.

Main Methods:

• Review of existing literature on AML classification systems.
• Analysis of data from cytogenetic and molecular profiling.
• Discussion of microarray applications in AML research.

Main Results:

• AML classification is multifaceted, incorporating morphology, cytogenetics, and molecular markers.
• Subtyping AML improves survival prediction but has limited impact on treatment, with exceptions like all-trans retinoic acid for AML-M3.
• NPM1 mutations without FLT3-ITD in normal karyotype AML influence treatment decisions regarding allogeneic stem cell transplantation.

Conclusions:

• Enhanced understanding of AML molecular biology is crucial for developing targeted therapies.
• Microarrays offer valuable insights into AML classification, prognosis, and pathobiology.
• Future AML treatments will likely involve personalized approaches, such as combining chemotherapy with tyrosine kinase inhibitors.